RHP 5.54MTRN 4.28PSMT 0ESLOY 0MSFT -8.48META -4.53HLPR.TO 0VDY.TO -0.65
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

24.04
-0.68 (2.75%)
as of Jun 24, 2026, 8:00:00 pm Market Open.
581 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 24, 2026, 12:00 am

This summary was created by AI, based on 29 opinions in the last 12 months.

Pfizer Inc (PFE) is facing significant challenges including a patent cliff and the aftermath of over-earning during the COVID-19 pandemic. The company has made efforts to bolster its drug pipeline through acquisitions, such as Seagen, but many experts express concerns about the lack of earnings momentum and blockbusters to drive growth. While the stock offers an attractive dividend yield (around 6-7%), there is a prevailing sentiment around its long-term growth prospects as reliance on cost-cutting and strategic acquisitions seems insufficient. Analysts highlight the need for a new growth catalyst, particularly in oncology, to reassure investors as the dividend yield may be at risk if substantial progress with new drugs is not achieved. Overall, patience is emphasized by many experts, with a hope that the stock will eventually perform better amid potential improvements in government policies and market conditions.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
AstraZeneca, AZN
PAST TOP PICK

Pfizer Inc(PFE)

Oct 31, 2006
(A Top Pick July 11/06. Up 12.8%.) 3.6 % dividend. Still more upside. But pipeline. Money continues to flow into the multinationals, which will benefit this company.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$26.65

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 23, 2006
3.4% dividend. The stock has been steadily rising over the last four months. Should be a core holding.
Photo of Rob CallanderRob Callander
Owned
Unlock Rating
$27.73

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Oct 19, 2006
This group has been forgotten over the last 5 years as it wildly under-performed the market. They all went to virtually zero growth rate and now there is a pick up. There is cost cutting and they are under owned. Likes this space. This would not be his number one choice but it is okay.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$27.68

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Oct 17, 2006
Reached his model price and he sold his holdings.
Photo of Brian Acker, CABrian Acker, CA
No
Unlock Rating
$27.72

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 16, 2006
Pipeline has been a little hurt because of competition, but the valuation is as cheap as it has been in 20 years.
Photo of John ZechnerJohn ZechnerUnlock Rating
$27.66

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 10, 2006
His favourite large drug stock. Has been beaten up pretty badly. Has a great product pipeline, even with patents coming off. Swimming in cash. Doing a share buyback and have increased their dividends.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$27.56

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 04, 2006
Very cheap. Pays a nice yield. There were some issues with management and there has been a change. The pharmaceutical industry as a whole is undervalued.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$28.33

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Sep 27, 2006
The stock has increased since he picked it. They have raised their dividends. It has a high yield. He continues to own.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$28.41

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 18, 2006
Good value for a bounce. Expects another 15/20% upside. Treating it as a Trade, not for the long term.
Photo of Ross HealyRoss Healy
Owned
Unlock Rating
$28.16

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 22, 2006
Likes it and still buying for new clients. Have a pipeline of new drugs and using their cash to develop new drugs. Have sold their consumer products division. Have increased their dividends and doing buybacks.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$26.98

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 17, 2006
His 2 favourite pharmaceuticals are Glaxosmithkline (GSK-N) and Johnson & Johnson (JNJ-N). This company is having so much trouble right now that they are on their 3rd CEO in the last 5/6 years. Have patent problems and sales are declining. Outstanding lawsuits.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$27.00

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Aug 09, 2006
Big issue is 20% of revenue and a larger % of profits comes from one drug, Lipitor, which will get generic competition. Sold their consumer business and have other products in the pipeline and they are buying back mountains of its own stock. Dividend share is significant.
Photo of Brad WillockBrad Willock
No
Unlock Rating
$26.15

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Aug 03, 2006
A defensive position. Very cheap. Lots of value and seems to have momentum.
Photo of Ross HealyRoss Healy
Owned
Unlock Rating
$25.51

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Aug 02, 2006
(A Top Pick May 10/06. No change.) A large cap stock that is going into transition. Sold their consumer products area. Wants to see how this affects the balance sheet. 4% dividend. Still likes.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$25.61

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jul 25, 2006
All the major drug stocks are starting to act better. In the state of market, money moves from risky stocks to defensive stocks. Has a great yield. A good place to be.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$24.96

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
Showing 601 to 615 of 883 entries

You may also like

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

MSFT -8.48$365.46
PPL.TO -0.83$66.15
CVE.TO -1.49$35.09
TOU.TO -0.68$59.86
GOOG -1.04$345.04

Today's Top Picks

RHP 5.54$129.77
MTRN 4.28$269.62
PSMT 0$
ESLOY 0$95.66
MSFT -8.48$365.46

Popular Articles

Latest Sell Signals

ATD.TO 1.89$93.76
ITB 5.99$103.32
GLD -11.4$365.92
MU -3.26$1048.51
MU -3.26$1048.51

Most Recent Experts

Brendan Caldwell

Brendan Caldwell

Caldwell Securities

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

Paul Harris, CFA

Paul Harris, CFA

Harris Douglas Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically